Amarin Corp Plc (AMRN)

[Atom0aks]

There is no comparison in these trials and you know it. Why did you not include the other non-diabetic population? You make it appear there would only be one question for one of the populations and make it appear negative.

That's because I am predicting the question will revolve around just one population. But that's not my word, it's Amarin's:

analyses of the degree of treatment benefit in the different patient populations (i.e., subgroups) studied in REDUCE-IT and the sufficiency of the efficacy findings to support indications and the appropriate wording thereof in light of the patient characteristics of the populations studied; for example, as prespecified and previously disclosed, the established cardiovascular (CVD) disease secondary prevention cohort, which represented approximately 70% of enrolled patients in REDUCE-IT and had a high observed event rate, experienced a numerically higher effect size (27% relative risk reduction, or RRR) than the high-risk, mostly diabetic primary prevention cohort, which represented approximately 30% of enrolled patients and had a relatively lower observed event rate and experienced a 12% RRR;